Fulcrum Therapeutics (FULC) Research & Development (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Research & Development data on file, last reported at $14.1 million in Q1 2026.

• Research & Development for Q1 2026 came in at $14.1 million, up 5.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.8 million (changed 0.41% YoY), and the FY2025 annual result was $56.1 million, down 11.49% from the prior year.
• Research & Development eased to $14.1 million in Q1 2026 per FULC's latest filing, from $15.4 million in the prior quarter.
• Over five years, Research & Development peaked at $25.0 million in Q2 2022 and troughed at $11.7 million in Q4 2024.
• A 5-year average of $16.6 million and a median of $16.7 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2024: Research & Development soared 43.97% in 2022, then plunged 38.35% in 2024.
• A 5-year view of Research & Development shows it stood at $18.6 million in 2022, then grew by 2.33% to $19.0 million in 2023, then sank by 38.35% to $11.7 million in 2024, then jumped by 31.61% to $15.4 million in 2025, then retreated by 8.64% to $14.1 million in 2026.
• Business Quant data shows FULC's Research & Development at $14.1 million in Q1 2026, $15.4 million in Q4 2025, and $14.3 million in Q3 2025.